Table 1.

Performance characteristics of QC analytes fortified in a urine control. A separate urine aliquot was processed in each batch (n = 3 batches) and injected 6× throughout the batch for a total of 18 data points.

Name	Adduct	Δmass, range, all batches (ppm)	Peak Area CV%, all batches	Peak Area CV%, batch 1 (n = 6)	Peak Area CV%, batches 2 & 3 (n = 12)	Mean Retention Time (min), all batches (CV%)
quinoline	[M+H]+	−0.31 – 1.23	21.3	6.4	6.0	14.85 (1.7)
6-methylcoumarin	[M+H]+	−0.75 – 0.06	17.5	13.7	18.6	17.16 (0.3)
acetamiprid	[M+H]+	−1.12 – −0.18	31.3	1.5	9.0	13.46 (0.6)
carbamazepine	[M+H]+	−0.67 – 0.63	13.7	4.7	5.3	17.42 (0.1)
imidacloprid	[M+H]+	−1.72 – −0.39	40.5	7.1	15.9	12.01 (0.8)
sulfamethazine	[M+H]+	−1.50 – −0.64	94.9	1.1	28.6	8.99 (7.6)
buspirone	[M+H]+	−1.55 – −0.54	6.0	7.1	5.0	20.24 (5.5)
1-naphthol	[M-H]−	1.96 – 2.53	24.7	4.3	8.1	18.24 (0.2)
thymol	[M-H]−	2.28 – 2.35	22.5	10.5	11.9	19.47 (0.1)
bisphenol F	[M-H]−	1.76 – 1.81	25.3	7.8	6.1	17.22 (0.2)
2,4-D	[M-H]−	1.14 – 1.64	31.9	4.7	11.4	8.20 (44.4)
bisphenol A	[M-H]−	1.19 –1.50	27.5	6.3	7.5	18.50 (0.1)
bisphenol S	[M-H]−	0.44 – 0.76	29.4	4.7	5.3	13.56 (4.8)
hesperetin	[M-H]−	0.86 – 1.06	37.1	12.7	5.1	16.89 (3.3)
diflubenzuron	[M-H]−	1.00 – 1.29	14.5	5.1	8.3	19.76 (0.1)
chloramphenicol	[M-H]−	1.00 – 1.28	24.6	4.0	6.5	14.59 (0.6)
furosemide	[M-H]−	0.88 – 1.25	41.4	6.8	8.3	9.90 (29.6)
boscalid	[M-H]−	1.35 – 1.61	25.3	9.2	7.0	19.56 (0.1)
2,4,6-triiodophenol	[M-H]−	1.10 – 1.30	25.4	5.4	5.3	19.63 (3.0)